drugset
drugset / Trial / NCT02700373

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

NCT02700373 ↗

Phase 1 Completed 40 enrolled Hapten Sciences, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.

Timeline

Start
2016-03
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PDC-APB Unknown 0.125 mg Intramuscular
Subject PDC-APB Unknown 0.375 mg Intramuscular
Subject PDC-APB Unknown 1 mg Intramuscular
Subject PDC-APB Unknown 2.5 mg Intramuscular
Subject PDC-APB Unknown 10 mg Intramuscular

Indications

contact dermatitis